Results 131 to 140 of about 33,178 (262)

Setting the stage: the sleek cell-cycle machinery of the liverwort Marchantia polymorpha. [PDF]

Plant Cell
Robinson J.
europepmc   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source

Atomically precise metal cluster enzymes for pathological tissue regeneration

BMEMat, EarlyView.
Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong, Zhifeng Shi, Mengqing Li, Jien Han, Haoyan Chen, Maofei Ran, Shaojian Zhong, Limin Ma, Chengyun Ning, Youzhun Fan, Zhenghua Tang, Peng Yu   +11 more
wiley   +1 more source

SDC4 silencing promotes cell cycle arrest at the restriction point (R point) in anoikis-resistant endothelial cells. [PDF]

Cytotechnology
Ferreira BZF, Pereira DMC, Onyeisi JOS, Machado RS, Tamura RE, Nader HB, Lopes CC.   +6 more
europepmc   +1 more source

Pt‐TiO2 mesoporous nanosystem co‐delivering phlorezin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation

BMEMat, EarlyView.
Abstract Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO2 nanoparticles for the co‐delivery of Phlorezin, presenting a novel approach for HCC treatment through sonodynamic ...
Kairui Liu, Bo Zhang, Yue Wan, Zhiru Yang, Abdusami Abdurahman, Mengxin He, Shengtao Hu, Yi Zhang, Xiaoke Li, Jin Chang, Jun Kang, Liren Liu, Wanghua Liu, Shao Li   +13 more
wiley   +1 more source

Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors. [PDF]

J Hematol Oncol
Safaroghli-Azar A, Mekonnen LB, Lenjisa J, Milne R, Wang S.   +4 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

KRAS (G12D)-selective inhibitor MRTX1133 suppresses proliferation and differentially modulates chemosensitivity in ovarian mucinous carcinoma. [PDF]

Oncol Lett
Watano R, Mizukami H, Saga Y.
europepmc   +1 more source

Dual Regulatory Functions of Classical Zinc Finger Clusters from Myeloid Zinc Finger‐1

Chemistry – A European Journal, EarlyView.
The classical zinc finger (ZF) protein MZF1 uses two ZF clusters to achieve metal‐dependent and gene‐specific promoter recognition. The differential redox stability and modular utilization of the two ZF clusters enable MZF1 to regulate cerebrovascular, neuronal, and cancer‐related transcriptional programs.
Yunha Hwang, Yerim Park, Nohwan Park, Heeju Noh, Hyun Goo Kang, Seung Jae Lee   +5 more
wiley   +1 more source

PROTACs for Collateral Degradation: Is It Time to Back Up the Bus? [PDF]

ACS Med Chem Lett
Gao ZG, Burgess K.
europepmc   +1 more source